Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Portland, OR
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Bethlehem, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Bethlehem, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Danville, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Danville, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Lancaster, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Lancaster, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Langhorne, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Langhorne, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Pittsburgh, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sayre, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sayre, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wilkes-Barre, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Willow Grove, PA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Willow Grove, PA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Providence, RI
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Charleston, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Columbia, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Columbia, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Greenville, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Spartanburg, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sumter, SC
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sumter, SC
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chattanooga, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cookeville, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cookeville, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Knoxville, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Memphis, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Nashville, TN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Amarillo, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Amarillo, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Grapevine, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Grapevine, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Round Rock, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Round Rock, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Tyler, TX
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tyler, TX
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Ogden, UT
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Ogden, UT
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Salt Lake City, UT
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fairfax, VA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fairfax, VA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Roanoke, VA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Roanoke, VA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Everett, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Everett, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Seattle, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Spokane, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Tacoma, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Vancouver, WA
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Vancouver, WA
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Madison, WI
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Milwaukee, WI
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
C.a.b.a.,
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
C.a.b.a.,
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fort Smith, AR
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fort Smith, AR
Click here to add this to my saved trials
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Saint Louis Park, MN
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Cardiovascular Disease Screening
Suburban/NHLBI Cardiovascular Disease Screening Protocol
Status: Enrolling
Updated:  12/31/1969
Suburban Hospital
mi
from
Bethesda, MD
Cardiovascular Disease Screening
Suburban/NHLBI Cardiovascular Disease Screening Protocol
Status: Enrolling
Updated: 12/31/1969
Suburban Hospital
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cardiovascular Disease Screening
Suburban/NHLBI Cardiovascular Disease Screening Protocol
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Cardiovascular Disease Screening
Suburban/NHLBI Cardiovascular Disease Screening Protocol
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer
Breast Clinic Strength and Range of Motion Study
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer
Breast Clinic Strength and Range of Motion Study
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Dexamethasone for Symptom Burden in Advanced Cancer Patients
The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Lyndon Baines Johnson Hospital
mi
from
Houston, TX
Dexamethasone for Symptom Burden in Advanced Cancer Patients
The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Lyndon Baines Johnson Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Dexamethasone for Symptom Burden in Advanced Cancer Patients
The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dexamethasone for Symptom Burden in Advanced Cancer Patients
The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Quality of Life for Prostate Proton Therapy
Prospective Evaluation of Quality of Life After Proton Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Quality of Life for Prostate Proton Therapy
Prospective Evaluation of Quality of Life After Proton Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Anchorage, AK
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Anchorage, AK
Click here to add this to my saved trials
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fairbanks, AK
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fairbanks, AK
Click here to add this to my saved trials